Trump's Marijuana Rescheduling Order Faces Delays at DEA, Impacting Canopy Growth
In December of the previous year, former President Donald Trump signed Executive Order 14370 to expedite marijuana rescheduling from Schedule I to III. This move initially boosted cannabis stocks like Canopy Growth (CGC), which saw a short-lived price surge before retreating. As of October 26, CGC is trading at $0.72 with a slight increase. On September 29, the DEA's Chief Administrative Judge issued a temporary stay on rescheduling due to legal challenges and pending analysis from the GAO report. The process has been delayed further as parties opposing rescheduling seek additional time to respond to the DEA’s objections. This uncertainty is weighing on investor sentiment for Canopy Growth. Despite these developments, broader issues such as operating losses and potential equity dilution are more critical concerns for Canopy Growth than U.S. regulatory delays. The company remains heavily reliant on its Canadian market, where challenges persist.
Tickers: $CGC
Topics: Canopy Growth stock movement DEA action marijuana rescheduling